mersana_logo.png
Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021 16:01 ET | Mersana Therapeutics, Inc.
- Initiated UPLIFT single-arm registration strategy for evaluation of UpRi in platinum-resistant ovarian cancer- Ended first quarter of 2021 with $228 million in cash CAMBRIDGE, Mass., May 10, 2021 ...
mersana_logo.png
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2021 Financial Results and Business Updates
May 03, 2021 08:00 ET | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
mersana_logo.png
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 28, 2021 16:05 ET | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
mersana_logo.png
Mersana Therapeutics Announces Appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer
April 26, 2021 08:00 ET | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
mersana_logo.png
Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting
April 10, 2021 09:00 ET | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
mersana_logo.png
Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path
April 09, 2021 08:15 ET | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
mersana_logo.png
Mersana Therapeutics Announces Initiation of UPLIFT Single-Arm Registration Strategy for UpRi in Platinum-Resistant Ovarian Cancer
April 09, 2021 08:00 ET | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
mersana_logo.png
Mersana Therapeutics Announces Publication of Two Manuscripts Detailing Preclinical Studies of the Dolaflexin Platform and Upifitamab Rilsodotin (XMT-1536) in AACR Journal Molecular Cancer Therapeutics
March 15, 2021 10:15 ET | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
mersana_logo.png
Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors
March 11, 2021 08:00 ET | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
mersana_logo.png
Mersana Therapeutics to Present Three Posters at Upcoming Virtual 2021 American Association for Cancer Research Annual Meeting
March 10, 2021 16:35 ET | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...